Fine-mapping across diverse ancestries drives the discovery of putative causal variants underlying human complex traits and diseases

Kai Yuan[1,2,3], Ryan J. Longchamps[1,2,3], Antonio F. Pardiñas[4], Mingrui Yu[1,2,3], Tzu-Ting Chen[5], Shu-Chin Lin[5], Yu Chen[6], Max Lam[1,3,7,8,9], Ruize Liu[1,2,3], Yan Xia[1,2,3], Zhenglin Guo[2], Wenzhao Shi[10], Chengguo Shen[10], The Schizophrenia Workgroup of Psychiatric Genomics Consortium[§], Mark J. Daly[1,2,3], Benjamine Neale[1,2,3], Yen-Chen A. Feng[11], Yen-Feng Lin[5,12,13], Chia-Yen Chen[14], Michael O'Donovan[4], Tian Ge[2,15,16]*, Hailiang Huang[1,2,3]*

Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA, USA
Stanley Center for Psychiatric Research, the Broad Institute of MIT and Harvard, Cambridge, MA, USA
Department of Medicine, Harvard Medical School, Boston, MA, USA
MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University School of Medicine, Cardiff, UK
Center for Neuropsychiatric Research, National Health Research Institutes, Miaoli, Taiwan
Center for Medical Genetics & Hunan Key Laboratory of Medical Genetics, School of Life Sciences and Department of Psychiatry, The Second Xiangya Hospital, Central South University, Changsha, China
Human Genetics, Genome Institute of Singapore, Singapore, Singapore
Division of Psychiatry Research, the Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA
Research Division Institute of Mental Health Singapore, Singapore, Singapore
Digital Health China Technologies Corp. Ltd., Beijing, China
Institute of Epidemiology and Preventive Medicine, College of Public Health, National Taiwan University, Taipei, Taiwan
Department of Public Health & Medical Humanities, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan
Institute of Behavioral Medicine, College of Medicine, National Cheng Kung University
Biogen, Cambridge, MA, USA
Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA, USA
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

§A list of members is available in the supplementary information
*Email: tge1@mgh.harvard.edu (T.G.); hhuang@broadinstitute.org (H.H.)

Abstract

Genome-wide association studies (GWAS) of human complex traits or diseases often implicate genetic loci that span hundreds or thousands of genetic variants, many of which have similar statistical significance. While statistical fine-mapping in individuals of European descent has made important discoveries, cross-population fine-mapping has the potential to improve power and resolution by capitalizing on the genomic diversity across ancestries. Here we present SuSiEx, an accurate and computationally efficient method for cross-population fine-mapping, which builds on the single-population fine-mapping framework, Sum of Single Effects (SuSiE). SuSiEx integrates data from an arbitrary number of ancestries, explicitly models population-specific allele frequencies and LD patterns, accounts for multiple causal variants in a genomic region, and can be applied to GWAS summary statistics when individual-level data is unavailable. We comprehensively evaluated SuSiEx using simulations, a range of quantitative traits measured in both UK Biobank and Taiwan Biobank, and schizophrenia GWAS across East Asian and European ancestries. In all evaluations, SuSiEx fine-mapped more association signals, produced smaller credible sets and higher posterior inclusion probability (PIP) for putative causal variants, and retained population-specific causal variants.

58
INTRODUCTION
60

Genome-wide association studies (GWAS) of human complex traits or diseases often implicate genetic loci that span hundreds or thousands of genetic variants, many of which have similar statistical significance. These loci may contain one or a handful of causal variants, while the associations of other variants are driven by their linkage disequilibrium (LD) with the causal variant(s). Statistical fine-mapping refines a GWAS locus to a smaller set of likely causal variants to facilitate interpretation and computational and experimental functional studies. Fine-mapping studies in samples of European ancestry have made important advances, with some disease-associated loci resolved to single-variant resolution[1–3]. Since non-causal variants tagging causal signals have marginally different effects across populations due to differences in LD patterns, cross-population fine-mapping, which integrates data from multiple populations and capitalizes on the genomic diversity across ancestries (e.g., smaller LD blocks in African populations), holds the promise to further improve fine-mapping resolution.

Cross-population fine-mapping analysis can be broadly classified into three categories, namely the meta-analysis-based approach, the *post hoc* combining approach, and Bayesian statistical methods (Figure 1). The meta-analysis-based approach applies single-population fine-mapping methods to meta-analyzed GWAS summary statistics and LD matrices, and has been widely used in the field, including in several seminal studies[4,5]. This approach, however, assumes no heterogeneity in effect sizes and LD patterns across populations, which is often not true and may lead to false positives and miscalibration of the inferred probability of a variant being causal[6]. The *post hoc* combining approach analyzes data from each population independently and integrates single-population fine-mapping results *post hoc*. While conducive to identifying population-specific causal variants[7], this approach fails to leverage the increased sample size, potential genetic correlations and LD diversity across populations to facilitate loci discovery and improve fine-mapping resolution, and may be sensitive to the choice of methods that combine population-specific results. Bayesian methods[8,9] provide a principled way to fine-map causal variants across populations and have been employed in the analyses of several complex traits or diseases[8–12]. That said, current cross-population Bayesian fine-mapping methods often suffer from inflated false positive rates, poor computational scalability, and inability to distinguish multiple causal signals in the same genomic locus, impeding their applications to emerging biobank-scale datasets of diverse ancestries.

Recently, Wang *et al.* proposed a single-population fine-mapping method, SUm of SIngle Effects (SuSiE)[13], which improved the calibration, computational efficiency and interpretation of statistical fine-mapping. Here, we extend the SuSiE model to a cross-population fine-mapping method, SuSiEx, which integrates multiple population-specific GWAS summary statistics and LD panels to enable more powerful and accurate fine-mapping. We evaluated the calibration, power, resolution and computational scalability of SuSiEx along with alternative fine-mapping methods via extensive simulations. We further used SuSiEx to fine-map 25 quantitative traits shared between the UK Biobank[14] and Taiwan Biobank[15], and to fine-map schizophrenia genetic risk loci across European and East Asian ancestries.

102
103
104 **RESULTS**
105
Overview of SuSiEx
SuSiEx extends the single-population fine-mapping model, SuSiE[13], by integrating population-
specific GWAS summary statistics and LD reference panels from multiple populations. In SuSiE,
the genetic influence on a trait or disease within a genomic locus is modeled as the summation
of several distinct effects, each contributed by a single causal variant, which naturally allows for
the modeling of multiple association signals and assigns each inferred putative causal variant to
a credible set with a posterior inclusion probability (PIP) (Figure 1). Building on this framework,
SuSiEx couples each single effect by assuming that the causal variants are shared across
populations (i.e., we report a single PIP rather than population-specific PIPs for each variant in a
credible set), while allowing them to have varying effect sizes (including null effects) across
ancestries. In addition, SuSiEx allows for a variant to be missing in an ancestry (e.g., due to its
low allele frequency), in which case the ancestry does not contribute to the PIP estimate,
effectively reducing the total sample size. Similar to SuSiE, SuSiEx builds on the Bayesian
variable selection in regression[16,17] and applies the iterative Bayesian stepwise selection[13] to
model fitting. Further modeling and computational details for SuSiEx are discussed in Methods.
121
Compared with the meta-analysis-based fine-mapping approach[4,5], SuSiEx explicitly models
population-specific GWAS summary statistics and LD patterns (Figure 1; Extended Data Figure
1a), which is expected to improve the fine-mapping resolution and more accurately control the
false positive rates, while allowing for heterogeneous effect sizes and retaining population-specific
causal variants (Extended Data Figure 1c). Compared with *post hoc* analysis to combine single-
population fine-mapping results[7], SuSiEx leverages the sample size, genetic correlation and LD
diversity across ancestries to improve the resolution of fine-mapping, especially for loci that are
under-powered to fine-map in individual datasets (Figure 1; Extended Data Figure 1b). Compared
with other Bayesian cross-population fine-mapping methods such as PAINTOR[9,18] and
MsCAIVAR[8], SuSiEx infers distinct credible sets for each causal signal (Figure 1), facilitating the
interpretation of fine-mapping results, and is orders of magnitudes more scalable computationally
(discussed later), enabling the analysis of large, complex loci and biobank-scale datasets across
many complex traits and diseases.
135

136
137 **Figure 1: Overview of fine-mapping methods.** An illustration of the inputs and outputs for
138 single-population and cross-population fine-mapping methods, the latter of which includes meta-
139 analysis-based approaches, *post hoc* combining approaches, previously published Bayesian fine-
140 mapping methods as well as SuSiEx.

141
142
143
144
SuSiEx outperformed single-population and naive cross-population fine-mapping
methods in simulations
We conducted a series of simulations to systematically evaluate the performance of SuSiEx.
Specifically, we generated simulation data under different numbers of causal variants (n_{csl}) per
locus, genetic correlations across populations (r_g) and SNP heritability (h^2) (Methods). To examine
the impact of these genetic parameters on fine-mapping results, we defined a standard simulation
setting with $n_{csl} = 1$, $r_g = 0.7$ and $h^2 = 0.1\%$, and then varied these parameters to produce a range
of local genetic architectures (Supplementary Tables 1 & 2). Given a set of genetic parameters,
we further assessed the impact of different population (European - EUR; African - AFR; East
Asian - EAS) and discovery sample size combinations (Supplementary Table 3) on fine-mapping
results. Throughout the simulation study, in single-population fine-mapping, we analyzed loci that
reached genome-wide significance in population-specific GWAS ($P<5\times10^{-8}$); in cross-population
fine-mapping, we analyzed loci that reached genome-wide significance in at least one of the
population-specific GWAS or in the cross-population fixed-effect meta-analysis. We assessed the
performance of different fine-mapping methods using an array of metrics: (i) Coverage/Calibration:
the proportion of credible sets that include at least one true causal variant across simulation
replicates; (ii) Power: the number of true causal variants identified (i.e., covered by a credible set);
(iii) Resolution: the size of credible sets and the number of fine-mapped variants with high
confidence (e.g., PIP >95%); (iv) Scalability: the computational cost/feasibility to perform fine-

mapping in large genomic loci; (v) Robustness: the proportion of runs in which the fine-mapping
algorithm converges and returns sensible results (defined later).
166
As expected, in the standard simulation setting (Figure 2; Supplementary Figures 1 & 2),
compared with single-population fine-mapping even with the same total sample size, integrating
data across populations using SuSiEx led to better power (i.e., more true causal variants being
identified; Figure 2a), had higher resolution (i.e., smaller credible sets and more causal variants
with high PIP; Figure 2b & 2d) and retained population-specific causal variants (Figure 2a & 2b).
Meanwhile, SuSiEx had well controlled coverage at 95%, regardless of the populations from
which data were combined (Figure 2c). The magnitude of improvements in power and resolution
is a result of both the increase in the total sample size and the LD diversity in the discovery
samples (Figure 2; Supplementary Table 4). For example, adding 50K EUR individuals to an
existing EUR sample of 50K individuals increased the number of identified causal variants with
PIP >95% from 18 to 26 and reduced the median size of the credible set from 11 to 8. The yield
of causal variants with PIP >95% was much greater (increased from 18 to 78) and the median
size of the credible set was much smaller (reduced from 11 to 5) if the added 50K individuals were
of AFR instead of EUR ancestry, demonstrating the importance of genetic diversity in cross-
population fine-mapping. The inclusion of 50K individuals of EAS ancestry also provided a greater
yield of causal variants with PIP >95% (increased from 18 to 44) and smaller credible sets
(reduced from 11 to 7) relative to adding 50K EUR samples, although the advantages were less
pronounced than when the AFR samples were added, due to the smaller LD blocks in the African
ancestries[19,20].
186
A widely used approach in recent multi-ancestry genetic studies[4] is to apply a single-population
fine-mapping method to meta-analyzed GWAS summary statistics and LD matrices (e.g., using a
sample size weighted approach). Despite of its convenience, this method can be miscalibrated
and does not unleash the full potential of genomic diversity, likely due to its over-simplified
modeling of LD across populations, the presence of population-specific variants, and the strong
assumption on cross-population effect size heterogeneity in fixed-effect meta-analysis[6]. We
confirmed, using the standard simulation setting, that fine-mapping using meta-analyzed GWAS
and sample size weighted LD suffered substantial loss in both power and coverage
(Supplementary Figures 3 & 4; Supplementary Table 5). In contrast, SuSiEx, through explicit and
flexible modeling of population-specific association statistics and LD, identified many more causal
variants (Supplementary Figure 4a) and was well calibrated (Supplementary Figure 4b).
198

Figure 2: The performance of SuSiEx in simulations. Simulated data were generated under the standard parameter setting (Methods). **a**, The number of identified true causal variants (true causal variants covered by a credible set) when integrating data from different populations with different sample sizes for fine-mapping. **b**, The number of true causal variants mapped to PIP >95%. **c**, The coverage of credible sets (the proportion of credible sets that contain a true causal variant). The dashed line indicates 95% coverage and error bars indicate 95% confidence intervals. **d**, Distribution of the size of credible sets. The upper and lower bounds of the box indicate the 75th and 25th percentiles, respectively. The middle line in the box indicates the median. In **a-d**, top labels of each subpanel indicate the total sample size, and the bottom panels indicate the sample size from each population. In **a** and **b**, we defined variants with MAF >0.5% only in one population as specific to that population, and all other variants as "shared" (i.e., shared variants across populations).

Another recently proposed strategy uses *post hoc* analysis to combine single-population fine-mapping results, which has been applied to multiple large-scale biobanks with promising biological discoveries[7]. However, this approach does not make use of subthreshold association signals, and does not leverage LD diversity to improve the resolution of fine-mapping. In simulations, SuSiEx found more true causal variants especially when the GWAS sample size is moderate or small, as expected for current non-EUR GWAS (Supplementary Table 5). For example, when analyzing 50K EUR and 20K AFR individuals under the standard simulation setting, the *post hoc* approach identified a smaller number of causal variants compared with SuSiEx (159 vs. 175). Although the numbers of true causal variants discovered by both approaches become closer when the GWAS sample sizes become larger, SuSiEx still outperformed *post hoc* analysis in resolution. In simulations, SuSiEx always identified more true causal variants with high PIP (50% or 95%) than *post hoc* analysis (Supplementary Figure 5 and Supplementary Table 5). For example, when analyzing 200K EUR and 200K AFR individuals under the standard simulation setting, the *post hoc* approach identified a smaller number of causal

229   variants with PIP > 95% compared with SuSiEx (140 vs. 161). And the median size of the credible
230   set was 10 vs. 8 when combining data from 50K EUR and 20K AFR individuals for *post hoc* and
231   SuSiEx respectively, and 4 vs. 2 when analyzing 200K EUR and 200K AFR individuals
232   (Supplementary Table 5).
233

SuSiEx outperformed existing Bayesian cross-population fine-mapping methods in
simulations
We further compared SuSiEx with two published Bayesian cross-population fine-mapping
methods, PAINTOR[9,18] and MsCAVIAR[8], using the standard simulation setting (Supplementary
Table 2). We noted that neither of the two methods is capable of analyzing all common variants
(MAF >1% in EUR, EAS or AFR) in a 1 Mb locus (6,548 variants per locus on average; Figure 3a,
left column). In particular, MsCAVIAR is not computationally scalable and cannot complete
analyzing a genetic locus within 24 hours, while PAINTOR always returned unreasonable results,
in which the sum of PIP across variants in a genomic locus >5 or <0.1. We note that in the
standard simulation setting, the number of true causal variants was set to one in each locus, and
thus a sum of PIP >5 or <0.1 appears "unreasonable" and may indicate severe model fitting issues
such as failure to converge. We then filtered the discovery summary statistics to fewer variants to
enable performance evaluation across methods. Specifically, we created three input datasets with
increasingly stringent selection criteria: "p < 0.05", "top 500" and "top 150", corresponding to
marginal P <0.05, the top 500 and the top 150 most associated variants, respectively. With these
filtered input datasets, the "enumerate" mode of PAINTOR, with the number of causal variants
set to one (which matched the simulation parameter, and was thus a favorable setting for
PAINTOR), still returned unreasonable results (sum of PIP >5 or <0.1) for approximately 25% of
the analyses (Figure 3a), while the "MCMC" mode of PAINTOR returned unreasonable results for
almost all the analyses, with zero PIP for every variant (Supplementary Table 6). The "enumerate"
mode of PAINTOR was also highly sensitive to the parameter "maximum number causal SNPs",
which is typically unknown *a priori* and difficult to set in practice (Extended Data Figure 2). The
other Bayesian fine-mapping method, MsCAIVAR, was only able to analyze the smallest input
dataset ("top 150"), as larger dataset took more than 24 hours per locus (Figure 3a), although the
results were generally "reasonable" (Extended data Figure 2; Supplementary Table 6).
259
260

Figure 3: Comparison of SuSiEx, PAINTOR and MsCAVIAR in simulations. a, The job completion summary (scalability and robustness) for Bayesian fine-mapping methods using different numbers of input variants. PAINTOR was run using the "enumerate" mode with "-enumerate=1" (which matched the simulation parameter). Unfinished: jobs taking longer than 24 hours wall time. Unreasonable: jobs returning unreasonable results, defined as the sum of PIP across variants in the genomic locus >5 or <0.1 (1 is expected). Successful: jobs completed within 24 hours of wall time and returned reasonable results. **b**, Number of identified true causal variants with PIP >50% (x-axis) versus the coverage of credible sets (y-axis) for different input datasets and fine-mapping methods. Only simulation runs that were completed within 24 hours and returned reasonable results were included.

For each method, we then focused on simulation runs that returned reasonable PIP estimates.
PAINTOR, with the "enumerate" mode and the number of causal variants set to one, had
calibrated results at 95% coverage and identified a similar number of high-PIP causal variants to
SuSiEx in the EUR-only and EUR + EAS fine-mapping (PIP >50%; Figure 3b). MsCAVIAR,
however, identified much fewer causal variants with PIP >50% (Figure 3b). This is because
MsCAVIAR tends to return large credible sets containing almost all the variants in the input
dataset, each having a small PIP (Supplementary Table 7). SuSiEx outperformed PAINTOR and
MsCAVIAR in the number of causal variants identified with PIP >50%, when AFR samples were
included in the discovery GWAS (Figure 3b), suggesting that SuSiEx can leverage genomic
diversity to fine-map more causal variants with high accuracy. For example, when combining
200K EUR and 200K AFR samples, SuSiEx identified 261 unique causal variants with PIP >50%
using the full GWAS summary statistics, comparing with 209 identified by PAINTOR and 7
identified by MsCAIVAR across the four input datasets (Figure 3b; Supplementary Table 7). We
note that the coverage for SuSiEx was well calibrated in most settings but dropped below 95%
when the top 150 most associated variants were used as input, likely due to information loss from
variant filtering. As using the full GWAS summary statistics as input was computationally tractable
and yielded optimal results for SuSiEx, we do not consider this a limitation for SuSiEx and do not
recommend any prefiltering of variants when using SuSiEx in practice.
294
SuSiEx is robust to varying cross-population genetic architectures
We further examined the calibration, power and resolution of SuSiEx by varying key parameters
in the standard simulation setting. The cross-population genetic correlation (r_g) can be less than
one for many complex traits and diseases[21]. SuSiEx accounts for imperfect genetic correlation by
allowing for varying genetic effects across populations. Using simulated data with r_g of 0.4, 0.7,
and 1.0, we confirmed that SuSiEx was robust to a range of r_g values, with good calibration and
similar power and resolution (Supplementary Figures 6-10; Supplementary Table 8). The local
heritability (h^2) and the number of causal variants (n_{csl}) per locus can differ across the genome for
a given trait or disease[1,22–24]. We set the heritability per locus to 0.05%, 0.1%, 0.2%, 0.3%, 0.4%
and 0.5%, and for a given per-locus heritability, varied n_{csl} from 1 to 5 with each genetic effect
drawn from a normal distribution (Methods). As expected, SuSiEx performed better when h^2
increased (Supplementary Figures 11-15; Supplementary Table 9) and n_{csl} decreased
(Supplementary Figures 16-20; Supplementary Table 10), which corresponds to higher per-
variant heritability and thus larger statistical power. Nonetheless, SuSiEx was always well
calibrated at 95% coverage (Supplementary Figures 12 & 17), and was able to capture multiple
causal variants in the same locus as n_{csl} increased.
311
We additionally assessed the robustness of SuSiEx under model misspecifications. SuSiEx
assumes that causal variants are shared across populations. While a reasonable assumption for
most genetic associations underlying human complex traits and diseases as supported by recent
studies[25–28], SuSiEx allows for different effect sizes (including null effects) of a causal variant
across populations, and thus can accommodate violations of this modeling assumption. We
empirically evaluated the robustness of SuSiEx by simulating variants that had non-zero effect
sizes in one population but were null in other populations. We found that adding null data had little
impact on fine-mapping results (Supplementary Figure 21 and Supplementary Table 11),

confirming the robustness of SuSiEx to model misspecifications. Lastly, we note that in-sample
LD is preferred in fine-mapping as it matches the correlation pattern between variants in the
discovery GWAS sample. Unfortunately, in-sample LD is not always available, especially in large-
scale GWAS comprising multiple cohorts. Using an external LD reference panel from a genetically
close population can be a pragmatic solution despite its limitations[6,29–31]. Here, we evaluated the
impact of LD mismatch on SuSiEx. Consistent with previous findings, analysis using in-sample
LD produced excellent calibration and power, while using external LD led to coverage and power
loss as the genetic distance between the external reference panel and the discovery sample
increased (Supplementary Figure 4 and Supplementary Table 12).
329
SuSiEx increased the power and resolution of fine-mapping in biobank analysis
Encouraged by simulation results, we applied SuSiEx to data from the Pan-UKBB project and the
Taiwan Biobank (TWB). The Pan-UKBB project is a multi-ancestry resource derived from the UK
Biobank (UKBB)[14] by analyzing six continental ancestry groups across 7,228 phenotypes. We
included summary statistics of EUR and AFR (N_{EUR} up to 419,807; N_{AFR} up to 6,570,
Supplementary Table 13) ancestries from Pan-UKBB. We additionally included TWB, one of the
largest biomedical databases in East Asia (N_{EAS} = 92,615) with close to 100,000 study
samples[15,32]. We selected 25 quantitative traits shared between Pan-UKBB and TWB
(Supplementary Table 13), and defined 13,420 genomic loci that reached genome-wide
significance in at least one of the single-population association analysis or the meta-analysis
across the three populations (Methods; Supplementary Table 14). We then performed single-
population fine-mapping using SuSiE, and cross-population fine-mapping using SuSiEx,
combining EUR, AFR and EAS data.
343
SuSiEx identified 14,400 credible sets across 9,826 loci, while single-population fine-mapping
identified 12,784, 48, and 1,475 credible sets for the EUR, AFR and EAS populations, respectively
(Supplementary Table 14). Aligning credible sets across analyses (Methods) led to 2,953 (20.5%)
credible sets identified by SuSiEx that were not identified by single-population fine-mapping
(Supplementary Table 14). Among the 14,400 credible sets, 1,413 (9.8%) credible sets reached
genome-wide significance in the meta-analysis but not in any population-specific GWAS (as
indexed by the maximum PIP variant), and thus would have been missed if fine-mapping was
only conducted in single populations (Supplementary Table 14; Extended Data Figure 3b as an
example). In addition to identifying and mapping more genetic associations through integrating
data from multiple populations, SuSiEx also improved fine-mapping resolution. Relative to single-
population fine-mapping in the EUR population, adding AFR and EAS data increased the average
of the maximum PIP for a variant across all aligned credible sets from 0.44 to 0.47 (P = 3.7x10^{-6};
two-sided t test), and reduced the average size of credible sets from 29.4 to 27.2 (P = 0.015; two-
sided t test; Figure 4a & 4b; Supplementary Table 15; Extended Data Figure 3a as an example).
Additionally, cross-population fine-mapping identified 2,485 putative causal variants with PIP >95%
(Figure 4c; Supplementary Table 16), among which 575 were not discovered by any single-
population fine-mapping. For example, SuSiEx identified a credible set containing a single variant
associated with total bilirubin at PIP >99%, a missense variant of *TRIM5* (rs11601507). This
credible set failed to reach genome-wide significance in any population and was thus missed in
single-population fine-mapping (Figure 5a and Extended Data Figure 4). Similarly, SuSiEx

identified a two-variant credible set associated with albumin that failed to reach genome-wide
significance in any population (Figure 5b; Extended Data Figure 5). The lead variant in the credible
set is an intron variant of *ALOX5AP* with PIP 97.4%. This variant was fine-mapped to be an eQTL
variant regulating the expression of *ALOX5AP* in whole blood (PIP >99%), artery aorta (PIP =
86.1%) and spleen (PIP = 77.9%) (Figure 5b; Extended Data Figure 5)[33]. In both examples,
SuSiEx identified putative causal variants and resolved a genetic locus to its gene target that
would have been missed if only single-population fine-mapping was performed.
371
Next, we restricted the comparison to loci that were mapped to a single credible set by both single-
and cross-population fine-mapping such that our results were not affected by multiple causal
variants in LD and the algorithm of credible set alignment. In these single-credible-set loci, SuSiEx
continued to outperform single-population fine-mapping in power and resolution, identifying more
credible sets with high confidence (best PIP >95%; Figure 4d), and improving the maximum PIP
of a credible set in general relative to single-population fine-mapping (P = 6.4e-5; two-sided t test;
Figure 4e). In particular, SuSiEx improved the maximum PIP of 30 credible sets from <80% to >95%
(Figure 4e; orange and red dots), among which 9 were improved from <50% to >95% (Figure 4e;
red dots). We note that the maximum PIP for one credible set dropped substantially, from 99% to
21%, in the cross-population fine-mapping (Figure 4e; blue dot). Further investigation of this locus
revealed that the putative causal variant (12-67643414-T-A) is located in a low complexity
genomic region, where the quality of variant calling and imputation may be negatively affected[34].
This variant is also represented in fewer than 50% of individuals in gnomAD v2.1.1 genomes[35],
and violates Hardy-Weinberg equilibrium.
386
Biobank analyses further confirmed that SuSiEx can retain population-specific causal variants
(Extended Data Figure 3c as an example). Despite a dominating EUR sample size, SuSiEx
recaptured 83% of the findings from single-population fine-mapping. A non-trivial proportion of
credible sets from single-population fine-mapping that were not captured by SuSiEx may be
driven by quality issues, defined as (i) the best PIP variant is in the low complexity region (LCR);
(ii) the best PIP variant is in allelic imbalance or violates Hardy Weinberg equilibrium in gnomAD[35];
or (iii) the best PIP variant is multi-allelic or colocalizes with indels at the same genomic position,
which might influence imputation quality. For example, 17.5% (29/166) of the putative causal
variants with PIPs dropped by 10-20% in cross-population fine-mapping relative to single-
population fine-mapping had quality issues, compared with 41.2% (7/17) of the variants with PIPs
dropped by >40% (Extended Data Figure 6). These results suggest that, through the joint
modeling of multiple populations and datasets, SuSiEx provides the additional benefit of
identifying and removing likely low-quality findings from single-population analyses.
400
We used Ensembl Variant Effect Predictor (VEP)[36] to annotate each variant into high, moderate
or low functional impact, as well as modifiers. As the inferred PIPs increased, the proportion of
variants with high impact clearly increased (Extended Data Figure 7), suggesting that confidently
fine-mapped variants were enriched among mutations of functional importance. In total, we
identified 2,286 high or moderate impact variants in 95% credible sets located in 1,630 genes.
Among these variants, 425 had a PIP greater than 50% (Supplementary Table 17), and 275 had
a PIP greater than 95% (Supplementary Table 18). There were 28 genes containing at least two

high/moderate impact SNPs with PIP greater than 95%, while only 23 were detected in the three single-population fine-mapping analyses. In particular, *IQGAP2* and *PIEZO1* carried 3 missense variants associated with multiple blood biomarkers with PIPs >95%.

Figure 4: Cross-population fine-mapping analysis in biobanks. a, The distribution of the maximum PIP from all credible sets. **b**, The distribution of the size of all credible sets. **c**, The number of variants mapped to PIP >95% for all credible sets. **d**, The number of variants mapped to PIP >95% in single-credible-set loci. **e**, The maximum PIP from SuSiEx versus the maximum value of the maximum PIP in the three single-population fine-mapping using SuSiE. Only genomic loci with a single credible set aligned across analyses were included. **f** and **g**, The marginal per-allele effect size of the maximum PIP variant in EUR vs. EAS and EUR vs. AFR populations. We included variants in single-credible-set loci with PIP >95% estimated by SuSiEx and minor allele frequencies >5% in all populations. In **a-b**, red dots indicate the mean, the middle line in the box indicates the median, and the upper and lower bounds of the box indicate the 75th and 25th percentiles, respectively.

Lastly, we compared the per-allele effect sizes of high-confidence putative causal variants (PIP >95% in single- or cross-population fine-mapping) located in single-credible-set loci among

EUR, AFR and EAS populations (Figure 4f & 4g). As no secondary association was found in these
loci, we used marginal effect sizes in the comparison. Overall, the effect sizes were highly
concordant between EUR and EAS populations (r = 0.82) but less consistent between EUR and
AFR populations (r = 0.21), likely reflecting the larger uncertainties of the effect size estimates in
AFR samples due to the limited GWAS sample size. We suggest the nature and cause of such
inconsistency should be subject to a more thorough investigation with expanded non-European
resources. At the current state, the imperfect genetic correlations across populations suggested
the importance of accounting for variants with varying population-specific effect sizes in fine-
mapping models.
437

438
Figure 5. SuSiEx identified variants missed in single-population fine-mapping. Each sub-
figure consists of five panels, which are aligned vertically, with the x-axis representing the
genomic position. The top three panels visualize GWAS association statistics of the European
(Pan-UKBB Europan), African (Pan-UKBB African) and East Asian (Taiwan biobank) populations
following the LocusZoom[37] style. The second to bottom panel visualizes the fine-mapping results
from SuSiEx, which integrated GWAS summary statistics from the three populations. The bottom
panel shows gene annotations. For GWAS panels, the left y-axis represents the -log$_{10}$(p-value)
of each SNP. The gray horizontal dash line represents the genome-wide significance threshold
(5×10^{-8}). The purple rectangle for each locus represents the lead (most associated) variant.
Variants are colored by descending LD with the lead variant (ordered red, orange, green, light
blue, and dark blue dots). For fine-mapping panels, different colors were used to distinguish
different credible sets. The diamond represents the maximum PIP variant of each credible set. **a,**
Association with total bilirubin on chr11: 5,100,000-5,700,000. **b,** Association with albumin on
chr13: 31,150,000-31,450,000.
453
SuSiEx identified additional putative causal candidates for schizophrenia

We applied SuSiEx to schizophrenia GWAS summary statistics of EUR (N_{case} = 53,251, $N_{control}$ =
77,127) and EAS (N_{case} = 14,004, $N_{control}$ = 16,757) ancestries from the Psychiatric Genomics
Consortium (PGC), and fine-mapped the same 250 autosomal loci in the recent PGC publication[4].
SuSiEx successfully identified 215 credible sets out of 193 loci (not all loci converged to a credible
set, as in all fine-mapping analyses), among which 11 had a SNP with PIP >95% (Figure 6a;
Supplementary Tables 19 & 20). As expected, SuSiEx outperformed published PGC fine-mapping
results, which applied a single-population fine-mapping method, FINEMAP[38], to meta-analyzed
GWAS summary statistics and sample size weighted LD[4]. Specifically, SuSiEx mapped 57% (33
vs. 21) more signals to a single variant with PIP >50% in single-credible-set loci (Figure 6). Most
of the SuSiEx-improved credible sets had a marginally genome-wide significant signal (P-value
between 5E-8 and 1E-15; Figure 6b & 6c). SuSiEx also produced credible sets for three loci that
could not be resolved by FINEMAP in the original analysis. In these loci, FINEMAP inferred five
independent credible sets, each containing a single variant that was not statistically significant in
the GWAS, likely due to inaccurate reference panel[39]. Furthermore, SuSiEx substantially
increased the resolution of fine-mapping by reducing the average size of credible sets from 87.1
to 60.3 (P = 0.015; paired two-sided t test), and increasing the average of maximum PIP across
credible sets from 0.25 to 0.27 (P = 0.012; paired two-sided t test).
472

473
Figure 6: Fine-mapping of schizophrenia risk loci across European and East Asian
populations. a, The number of putative causal variants mapped to PIP >50% and >95% by
FINEMAP and SuSiEx in single-credible-set loci. **b,** The maximum PIP for each credible set within
single-credible-set loci, estimated by SuSiEx and FINEMAP. **c,** The difference of the maximum
PIP, estimated by SuSiEx and FINEMAP (y-axis), within each single-credible-set locus, plotted
against the -log$_{10}$(p-value) of the most associated variant in the cross-population meta-analysis.
In **b** and **c**, red dots represent credible sets with a maximum PIP >95% estimated by SuSiEx;
orange dots represent credible sets with a maximum PIP >50% estimated by SuSiEx.
482
483
484
485 **DISCUSSION**
486

487 We presented SuSiEx, a cross-population fine-mapping method which links multiple population-
488 specific sum of single effects (SuSiE) models by assuming the sharing of underlying causal
489 variants. Through flexible and accurate modeling of varying population-specific causal effect sizes
490 and LD patterns, SuSiEx improves the power and resolution of fine-mapping while producing well-
491 calibrated false positive rates and retaining the ability to identify population-specific causal
492 variants. We showed, via comprehensive simulation studies, that SuSiEx is highly computationally
493 efficient, outperforms alternative cross-population fine-mapping methods in calibration, power and
494 resolution, and is robust to model misspecifications. In particular, as the two state-of-the-art
495 Bayesian cross-population fine-mapping methods, PAINTOR is sensitive to the predefined (yet
496 unknown) number of causal variants, while MsCAVIAR is computationally intractable when the
497 total number of input variants is greater than a few hundreds. Moreover, neither method has the
498 capacity to analyze summary statistics from a comprehensive set of common variants in loci
499 greater than 1MB. SuSiEx overcomes these limitations and offers effective and efficient cross-
500 population fine-mapping that can be applied on biobank-scale datasets for the first time.
501
502 SuSiEx is designed to flexibly integrate genomic data from multiple populations, where effect
503 sizes and/or LD patterns can be different. For two or more GWAS conducted in independent
504 samples from the same population where effect sizes and LD patterns are highly concordant, we
505 recommend a fixed-effect meta-analysis to combine these GWAS, which is often more statistically
506 powerful than modeling these GWAS separately in SuSiEx without imposing any assumptions on
507 the correlation of SNP effect sizes across samples. A recent study proposed SuSiE-inf[40], which
508 incorporates a term of infinitesimal effects in addition to a small number of single-variant causal
509 effects, and showed that the new model can produce more calibrated fine-mapping results. While
510 the calibration of SuSiEx was excellent in simulation studies, expanding the SuSiEx model to
511 include this feature in the future may improve the fine-mapping of complex traits and diseases
512 that have a highly polygenic architecture.
513
514 We note that throughout this work we tried to use in-sample LD reference panels for fine-mapping.
515 Mismatch between the LD of the discovery sample and the reference panel may produce spurious
516 credible sets and causal signals, especially in genomic loci that harbor strong association signals.
517 This has been shown in prior work[39] and our simulations studies, and is a limitation of all fine-
518 mapping methods. We therefore recommend using in-sample LD for SuSiEx whenever possible,
519 and applying aggressive filtering of low-quality variants and secondary credible sets in complex
520 genomic loci if external LD reference panels have to be used.
521
522 There are several limitations of SuSiEx and the present study. First, we restricted our analyses to
523 SNPs to avoid potential strand flippings and alignment errors when analyzing indels across
524 biobanks. This may produce false positives if fine-mapped SNP(s) are proxies for causal indels
525 or structural variations (SV). Second, we did not incorporate functional annotations into SuSiEx.
526 Adding functional priors to the model may improve fine-mapping resolution when multiple variants
527 in strong LD have similar statistical significance, and may aid prioritization of follow-up functional
528 studies. That said, the biology underlying the observed variant-phenotype association may be
529 complex, and the modeling of functional data may be error-prone and inflate false positive rates.
530 Extending the Bayesian framework of SuSiEx to leverage functional or other omics data by

introducing a proper prior to the model can be a promising future direction. Third, our cross-
population fine-mapping in biobanks had an encouraging but modest improvement over the
resolution of credible sets identified by European-only analyses, which was largely due to the
limited discovery sample size of the African GWAS. However, we have shown that the largest
improvements of SuSiEx come with the most diverse datasets, and thus expect that SuSiEx will
become increasingly useful as the scale of genomic research in underrepresented populations
continues to expand in global biobanks[41] and disease-focused consortia. Lastly, it remains
unclear how SuSiEx would perform in admixed samples, in which the local ancestry (and thus the
causal variants and their effect sizes) may vary from individual to individual. Developing and
evaluating statistical fine-mapping methods in populations with complex genetic ancestries is an
important future direction.
542
In summary, SuSiEx provides robust, accurate and scalable fine-mapping that integrates GWAS
summary statistics from diverse populations. Together with the ability to distinguish multiple
causal variants within a genomic region, SuSiEx enables the analysis of large, complex genomic
loci and aids the interpretation of fine-mapping results. Future work that combines SuSiEx with
the rapidly expanding non-European genomic resources may facilitate the discovery of
functionally-important disease-causing variants computationally and experimentally.
549
550
551 **METHODS**
552
553 **Cross-population Sum of Single Effect (SuSiEx) model**
554 **Model description**. We extend the "SUm of SIngle Effects" (SuSiE) regression model to fine-
555 mapping studies across multiple populations:
556

557
$$\boldsymbol{y}_s = \boldsymbol{X}_s \boldsymbol{\beta}_s + \boldsymbol{\epsilon}_s, \qquad \boldsymbol{\epsilon}_s \sim N(\boldsymbol{0}, \sigma_s^2 \boldsymbol{I}), \qquad s = 1, 2, \ldots, S,$$

558
$$\boldsymbol{\beta}_s = \sum_{l=1}^{L} \boldsymbol{b}_{sl}, \qquad \boldsymbol{b}_{sl} = \boldsymbol{\gamma}_l b_{sl}, \qquad \boldsymbol{\gamma}_l \sim Mult(1, \boldsymbol{\pi}), \qquad b_{sl} = N(0, \tau_{sl}^2),$$

559
where for an population s (e.g., European, Asian or African), $\boldsymbol{y}_s$ is a vector of standardized
phenotypes (zero mean and unit variance) from N_s individuals, $\boldsymbol{X}_s = [\boldsymbol{x}_{s1}, \boldsymbol{x}_{s2}, \ldots, \boldsymbol{x}_{sM}]$ is an
$N_s \times M$ matrix of standardized genotypes (each column $\boldsymbol{x}_{sj}$ is mean centered and has unit
variance) in a genomic region that harbors at least one strong association signal, $\boldsymbol{\beta}_s$ is a vector
of SNP effect sizes, and $\boldsymbol{\epsilon}_s$ is a vector of residuals with i.i.d. elements, each following a normal
distribution with zero mean and variance σ_s^2. We assume that $\boldsymbol{\beta}_s$ is the sum of L single-effect
vectors $\boldsymbol{b}_{sl}, l = 1, 2, \ldots, L$, each has exactly one non-zero element (equals to b_{sl}). The position of
the non-zero element is determined by the binary vector $\boldsymbol{\gamma}_l$, which follows a multinomial
distribution. $\boldsymbol{\pi} = [\pi_1, \pi_2, \ldots, \pi_M]^\mathrm{T}$ is a vector that gives the prior probability of a SNP being causal,
and τ_{sl}^2 is the prior variance on the effect size b_{sl} of the causal SNP. We note that all populations
share the same underlying causal SNPs ($\boldsymbol{\gamma}_l$ does not depend on s), but the effect sizes of a causal
SNP across populations are allowed to be different (b_{sl} depends on s).
572

Model fitting. Assuming σ_s^2 and τ_{sl}^2 are known, the SuSiEx model can be fitted using a simple extension of the iterative Bayesian stepwise selection (IBSS) algorithm. Specifically, with an initialization of the posterior mean effect size of $\boldsymbol{b}_{sl}$, denoted as $\bar{\boldsymbol{b}}_{sl}$ (e.g., $\bar{\boldsymbol{b}}_{sl} = 0$ for all s and l), the fitting procedure involves iteratively updating $\boldsymbol{b}_{sl}$, given estimates of other effects $\boldsymbol{b}_{sl'}, l' \neq l$, until convergence:

◇ Compute residuals:
$$\boldsymbol{r}_{sl} = \boldsymbol{y}_s - \sum_{l' \neq l} \boldsymbol{X}_s \boldsymbol{b}_{sl'}, \qquad s = 1,2,\ldots,S.$$

◇ Compute the posterior inclusion probabilities (PIPs):
$$\alpha_{lj} = \Pr(\gamma_{lj} = 1 | \boldsymbol{r}_{sl}, \boldsymbol{X}_s) = \frac{\pi_j \prod_{s=1}^{S} \mathrm{BF}(\boldsymbol{r}_{sl}, \boldsymbol{x}_{sj})}{\sum_{j'}^{M} \pi_{j'} \prod_{s=1}^{S} \mathrm{BF}(\boldsymbol{r}_{sl}, \boldsymbol{x}_{sj'})}, \qquad j = 1,2,\ldots,M,$$

where $\mathrm{BF}(\boldsymbol{r}_{sl}, \boldsymbol{x}_{sj}) = \frac{p(\boldsymbol{r}_{sl}|\boldsymbol{x}_{sj})}{p(\boldsymbol{r}_{sl}|\boldsymbol{x}_{sj}, b_{sl}=0)} = \sqrt{\frac{v_{sj}^2}{\tau_{sl}^2 + v_{sj}^2}} \exp\left(\frac{z_{slj}^2}{2} \frac{v_{sj}^2}{\tau_{sl}^2 + v_{sj}^2}\right),$

$\hat{b}_{slj} = (\boldsymbol{x}_{sj}^{\mathrm{T}} \boldsymbol{x}_{sj})^{-1} \boldsymbol{x}_{sj}^{\mathrm{T}} \boldsymbol{r}_{sl} = N_s^{-1} \boldsymbol{x}_{sj}^{\mathrm{T}} \boldsymbol{r}_{sl}, v_{sj}^2 = \sigma_s^2 (\boldsymbol{x}_{sj}^{\mathrm{T}} \boldsymbol{x}_{sj})^{-1} = \sigma_s^2 N_s^{-1}, z_{slj} = \hat{b}_{slj}/v_{sj}.$

◇ Update the posterior distribution for b_{sl}:
$$b_{sl}|\gamma_{lj} = 1, \boldsymbol{r}_{sl}, \boldsymbol{x}_{sj} \sim N\left(\mu_{slj}, \phi_{slj}^2\right),$$

where $\phi_{slj}^2 = \left(v_{sj}^{-2} + \tau_{sl}^{-2}\right)^{-1}, \mu_{slj} = (\phi_{slj}^2/v_{sj}^2)\hat{b}_{slj}.$

◇ Compute the posterior mean for $\boldsymbol{b}_{sl}$:
$$\bar{\boldsymbol{b}}_{sl} = \mathrm{E}[\boldsymbol{b}_{sl}|\boldsymbol{r}_{sl}, \boldsymbol{X}_s] = \boldsymbol{\alpha}_l \circ \boldsymbol{\mu}_{sl},$$

Where $\boldsymbol{\alpha}_l = [\alpha_{l1}, \alpha_{l2}, \ldots, \alpha_{lM}]^{\mathrm{T}}$, $\boldsymbol{\mu}_l = [\mu_{sl1}, \mu_{sl2}, \ldots, \mu_{slM}]^{\mathrm{T}}$, and $\circ$ is element-wise multiplication.

Credible sets. The PIPs $\boldsymbol{\alpha}_l$ can be used to compute a level-ρ credible set $CS(\boldsymbol{\alpha}_l; \rho)$, which has a probability no less than ρ of containing at least one causal SNP. Specifically, let $(i_1, i_2, \ldots, i_M)$ denote the indices that sort α_{lj} in decreasing order, i.e., $\alpha_{li_1} > \alpha_{li_2} > \cdots > \alpha_{li_M}$, and let $S_k = \sum_{j=1}^{k} \alpha_{li_j}$. Then $CS(\boldsymbol{\alpha}_l; \rho) := \{i_1, i_2, \ldots, i_{k_0}\}$, where $k_0 = \min\{k: S_k \geq \rho\}$. When L exceeds the number of detectable effects in the data, some $\boldsymbol{\alpha}_l$ become diffuse and the corresponding credible sets will be large, containing many uncorrelated SNPs. Such credible sets have no inferential value and can be discarded if they have purity below a threshold (e.g., 0.5), where purity is defined as the smallest absolute correlation among all pairs of variants within the credible set.

Using GWAS summary statistics. Let $\hat{\beta}_{sj} = (\boldsymbol{x}_{sj}^{\mathrm{T}} \boldsymbol{x}_{sj})^{-1} \boldsymbol{x}_{sj}^{\mathrm{T}} \boldsymbol{y}_s = N_s^{-1} \boldsymbol{x}_{sj}^{\mathrm{T}} \boldsymbol{y}_s$ denote the marginal least squares effect size estimate of SNP j in the ethnic group s, and $\boldsymbol{D}_s = [\boldsymbol{d}_{s1}, \boldsymbol{d}_{s2}, \ldots, \boldsymbol{d}_{sM}] = \boldsymbol{X}_s^{\mathrm{T}} \boldsymbol{X}_s / N_s$ denote the LD matrix for ethnic group s, which can be estimated using an LD reference panel. Note that $\boldsymbol{x}_{sj}^{\mathrm{T}} \boldsymbol{r}_{sl} = \boldsymbol{x}_{sj}^{\mathrm{T}} \boldsymbol{y}_s - \boldsymbol{x}_{sj}^{\mathrm{T}} \sum_{l' \neq l} \boldsymbol{X}_s \bar{\boldsymbol{b}}_{sl'} = N_s \hat{\beta}_{sj} - N_s \sum_{l' \neq l} \boldsymbol{d}_{sj}^{\mathrm{T}} \bar{\boldsymbol{b}}_{sl'}$. Therefore, IBSS can be turned into a summary statistics based algorithm.

609
The multi-step model fitting approach. To determine the maximum number of single effects L,
we designed a heuristic, multi-step model fitting approach. Specifically, we start with L = 5 and fit
the SuSiEx model. If the model does not converge, we sequentially reduce L by 1 until the
algorithm converges. If the model converges with L = 5 and returns 5 credible sets, suggesting
that more than 5 credible sets may exist, we set L = 10 and rerun the model fitting algorithm. If
the model does not converge with L = 10, we sequentially reduce L by 1 until the algorithm
converges.
617
Simulations
Genomic data. We simulated individual-level genotypes of EUR, EAS and AFR populations using
HAPGEN2[42] with ancestry-matched 1000 Genomes Project (1KG) Phase III[43] superpopulation
samples as the reference panel. We grouped CEU, IBS, FIN, GBR and TSI into the EUR
superpopulation, CDX, CHB, CHS, JPT and KHV into the EAS superpopulation, and ESN, MSL,
LWK, GWD and YRI into the AFR superpopulation. To calculate the genetic map (cM) and
recombination rate (cM/Mb) for each superpopulation, we downloaded the maps and rates for
their constituent subpopulations (Data availability), linearly interpolated the genetic map and
recombination rate at each position (Code availability), and averaged the genetic maps and
recombination rates across the subpopulations in each superpopulation. We simulated 400,000
EUR samples, 200,000 EAS samples and 200,000 AFR samples, and confirmed that the allele
frequencies and LD patterns of the simulated genotypes were highly similar to those of the 1KG
reference panels. We randomly selected 100 1MB regions from chromosome 1 (Supplementary
Table 1), and filtered for bi-allelic common (MAF >1%) SNPs in at least one of the three
superpopulations.
633
Phenotypic data. We randomly selected n_{csl} causal variants within each genomic locus. The
allelic effect sizes of each selected causal variant for the EUR, EAS and AFR populations were
generated under a multivariate normal distribution $\mathrm{N}(\mathbf{0}, \Sigma_{3\times3})$, where $\Sigma_{3\times3}$ was defined as, $\Sigma_{ij} = 1$,
if $i = j$, and $\Sigma_{ij} = r_g$, if $i \neq j$ where r_g is the genetic correlation between populations. For each locus,
we then generated the phenotype by adding a normally distributed noise term to the genetic
component to produce the given per-locus heritability h^2.
640
To assess SuSiEx in a wide range of settings, we generated simulation data with varying genetic
correlations (r_g), per-locus heritability (h^2), and the number of causal variants (n_{csl}) per locus. We
defined a standard simulation setting using n_{csl} = 1, r_g = 0.7 and h^2 = 0.1%. We then varied r_g (r_g
= 0.4 and 1.0) to reflect different levels of cross-population genetic correlations, varied h^2 (h^2 =
0.05%, 0.2%, 0.3%, 0.4% and 0.5%) to reflect different per-locus heritability values, and varied
n_{csl} (n_{csl} = 2, 3, 4, 5) with h^2 = 0.5% to reflect the scenario of multiple causal variants in a genomic
locus. To evaluate the robustness of SuSiEx to model misspecification, we simulated 200K EUR
and 200K AFR samples with no causal variants, and included these null data in cross-population
fine-mapping. For each parameter setting, we replicated the simulation five times for each locus
(Supplementary Table 2), producing 500 simulation runs.
651

652 **Association analysis and LD calculation.** We used the linear regression implemented in
653 PLINK[44] to generate GWAS summary statistics, and calculated in-sample LD for each genomic
654 locus. To evaluate the impact of LD mismatch on fine-mapping results, we additionally calculated
655 LD matrices using subpopulation samples within the EUR and AFR superpopulations.
656
Fine-mapping analysis with SuSiEx, SuSiE, PAINTOR, and MsCAVIAR.
We compared SuSiEx, SuSiE, PAINTOR and MsCAVIAR using the standard simulation setting.
SuSiEx and SuSiE were performed and evaluated on additional settings beyond the standard
simulations. As PAINTOR and MsCAVIAR are not computationally scalable to full GWAS
summary statistics, we restricted the analysis to three filtered sets of variants: "p < 0.05", "top 500"
and "top 150", corresponding to marginal p-values <0.05, the top 500 and the top 150 most
associated variants from GWAS, respectively. PAINTOR provides two model fitting options,
"MCMC" and "enumerate". The "MCMC" mode automatically learns the number of causal variants
in a locus while the "enumerate" mode requires pre-setting the maximum number of causal
variants. We ran PAINTOR using "-mcmc", "-enumerate=1", "-enumerate=2" and "-enumerate=3".
All other parameters were set to default. We set the maximum runtime to 24 hours in our high-
performance computing (HPC) system, the maximum memory to 8 GB, and the number of CPUs
to one. For SuSiEx, we used the multi-step model fitting approach described above to determine
the number of causal variants. Credible sets that did not contain any genome-wide significant
variant (marginal P <5E-8) in any single-population GWAS nor cross-population meta-GWAS
were filtered out. We ran MsCAVIAR with the default parameters and set the confidence level of
credible sets as 0.95.
674
Biobank analysis
Cohorts. GWAS summary statistics of 25 quantitative traits, available from both the UK Biobank
(UKBB) and Taiwan Biobank (TWB), were used in our biobank fine-mapping analysis
(Supplementary Table 13). European (EUR; N_{EUR} up to 419,807) and African (AFR; N_{AFR} up to
6,570) GWAS summary statistics were obtained from the Pan-ancestry genetic analysis of the
UK Biobank (Pan-UKBB). East Asian GWAS summary statistics were obtained from the Taiwan
Biobank (EAS; N_{EAS} = 92,615).
682
Loci definition. We used a 6-way LD clumping-based method to define the genomic loci, using
1KG data as the LD reference for clumping. CEU, GBR, TSI, FIN and IBS were combined as the
reference for the EUR population; ESN, GWD, LWK, MSL and YRI were combined as the
reference for the AFR population; CHB, CHS, CDX, JPT and KHV were combined as the
reference for the EAS population. We extracted all variants with MAF >0.5%, and for each of the
25 traits, performed the LD clumping in the three populations using the corresponding reference
panel and PLINK[44]. To include loci that reached genome-wide significance (P <5E-8) only in the
meta-analysis, we further performed clumping for the meta-GWAS across the three populations,
using the three reference panels, respectively. For each clumping, we set the p-value threshold
of the leading variant as 5e-8 (--clump-p1) and the threshold of the tagging variant as 0.05 (--
clump-p2), and set the LD threshold as 0.1 (--clump-r2) and the distance threshold as 250 kb (--
clump-kb). We then took the union of the 6-way LD clumping results and extended the boundary

of each merged region by 100 kb upstream and downstream. Finally, we merged adjacent loci if
the LD (r^2) between the leading variants was larger than 0.6 in any LD reference panel.
697
698 **In-sample LD calculation.** We used the in-sample LD of the three populations in the fine-
699 mapping analysis. We extracted all variants with MAF >0.5% from each population and calculated
700 the LD using PLINK[44]. Multi-allelic variants and indels were excluded to avoid potential strand
701 flipping and alignment errors.
702
703 **Fine-mapping.** We applied SuSiEx to the 25 quantitative traits to integrate GWAS summary
704 statistics derived from the three populations. We filtered out credible sets that did not contain any
705 genome-wide significant variant (p <5E-8) in any population-specific GWAS or cross-population
706 meta-GWAS.
707
Credible set alignment. To compare the results between single-population and cross-population
fine-mapping, we aligned the inferred credible sets across the four sets of analyses using a
weighted Jaccard similarity index-based method[7]. Specifically, for a given pair of overlapping
credible sets in a genomic locus, we computed the PIP-weighted Jaccard similarity index, defined
as $\sum_i min(x_i, y_i) / \sum_i max(x_i, y_i)$, where x_i and y_i are PIP values (or zero if missing) for the same
variant i from the two credible sets. Pairs of credible sets with a similarity index greater than 0.1
were aligned. If one credible set can be aligned with multiple credible sets, the set with the highest
similarity was selected.
716
Cross-population fine-mapping in schizophrenia cohorts.
Schizophrenia GWAS summary statistics of European (EUR; N_{case} = 53,251, $N_{control}$ = 77,127) and
East Asian (EAS; N_{case} = 14,004, $N_{control}$ = 16,757) ancestries were obtained from the recently
published Psychiatric Genomics Consortium (PGC) schizophrenia analysis[4]. We fine-mapped the
same 255 loci defined in the PGC publication. We calculated LD by applying LD-Store v1.1[39] to
each cohort and locus, and then calculated an effective sample size weight LD matrix[45] across
cohorts for the EUR and EAS populations, respectively (Code availability; LDmergeFM). We
applied SuSiEx to integrate EUR and EAS schizophrenia GWAS summary statistics to perform
cross-population fine-mapping. Credible set level was set to 99%. Credible sets that did not
contain any genome-wide significant variant (marginal P <5E-8) in single-population GWAS or
cross-population meta-GWAS were filtered out.
728
DATA AVAILABILITY
Publicly available data are available from the following sites:
1KG Phase 3 reference panels: https://mathgen.stats.ox.ac.uk/impute/1000GP_Phase3.html;
Genetic map for each subpopulation:
https://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination_rat
es;
PanUKBB summary statistics: https://pan.ukbb.broadinstitute.org/downloads;
TWB data used in this study contain protected health information and are thus under controlled
access. Application to access such data can be made to the TWB
(https://www.twbiobank.org.tw/new_web_en/);

PGC schizophrenia GWAS: https://pgc.unc.edu/for-researchers/download-results
740
CODE AVAILABILITY
The code used in this study is available from the following websites:
SuSiEx: https://github.com/getian107/SuSiEx;
PAINTOR: https://github.com/gkichaev/PAINTOR_V3.0;
MsCAVIAR: https://github.com/nlapier2/MsCAVIAR;
HAPGEN2: https://mathgen.stats.ox.ac.uk/genetics_software/hapgen/hapgen2.html;
PLINK1.9: https://www.cog-genomics.org/plink;
LDmergeFM: https://github.com/Pintaius/LDmergeFM
749
ETHICS
Collection of the UKBB data was approved by the Research Ethics Committee of the UKBB.
UKBB individual-level data used in the present work were obtained under application no. 32568.
Collection of the TWB data was approved by the Ethics and Governance Council (EGC) of TWB
and the Department of Health and Welfare, Taiwan (Wei-Shu-I-Tzu no.1010267471). TWB
obtained informed consent from all participants for research use of the collected data. Access
to, and use of, TWB data in the present work was approved by the EGC of TWB (approval
number: TWBR10907-05) and the Institutional Review Board of National Health Research
Institutes, Taiwan (approval number: EC1090402-E).
759

ACKNOWLEDGMENTS
UKBB European and African GWAS summary statistics were obtained from the PanUKBB Project.
We thank the Schizophrenia Working Group of the Psychiatric Genomic Consortium (PGC) for
providing the GWAS summary statistics and in-sample LD for the schizophrenia analysis. H.H.
acknowledges supports from National Institute of Diabetes and Digestive and Kidney Diseases
(NIDDK) K01DK114379 and R01DK129364, National Institute of Mental Health (NIMH)
U01MH109539 and R01MH130675, Brain and Behavior Research Foundation Young
Investigator Grant (28450), the Zhengxu and Ying He Foundation, and the Stanley Center for
Psychiatric Research. T.G. is supported by National Institute on Aging (NIA) R00AG054573 and
National Human Genome Research Institute (NHGRI) R56HG012354. Y.F.L. is supported by the
National Health Research Institutes (NP-109-PP-09), and the Ministry of Science and Technology
(109-2314-B-400-017) of Taiwan.
772

773 **COMPETING INTERESTS**
774 W.S. and C.S. are employees of Digital Health China Technologies Corp. Ltd.. M.J.D. is a founder
775 of Maze Therapeutics. C.Y.C. is an employee of Biogen. H.H. received consultancy fees from
776 Ono Pharmaceutical and honorarium from Xian Janssen Pharmaceutical.
777

REFERENCES

1. Huang, H. *et al.* Fine-mapping inflammatory bowel disease loci to single-variant resolution.

Nature **547**, 173–178 (2017).

2.   Maller, J. B. *et al.* Bayesian refinement of association signals for 14 loci in 3 common

diseases. *Nat. Genet.* **44**, 1294–1301 (2012).

3.   Identification of multiple risk variants for ankylosing spondylitis through high-density

genotyping of immune-related loci. *Nat. Genet.* **45**, 730–738 (2013).

4.   Consortium, T. S. W. G. of T. P. G., The Schizophrenia Working Group of the Psychiatric

Genomics Consortium, Ripke, S., Walters, J. T. R. & O'Donovan, M. C. Mapping genomic

loci prioritises genes and implicates synaptic biology in schizophrenia. Preprint at

https://doi.org/10.1101/2020.09.12.20192922.

5.   Mahajan, A. *et al.* Multi-ancestry genetic study of type 2 diabetes highlights the power of

diverse populations for discovery and translation. *Nat. Genet.* **54**, 560–572 (2022).

6.   Kanai, M. *et al.* Meta-analysis fine-mapping is often miscalibrated at single-variant

resolution. *bioRxiv* (2022) doi:10.1101/2022.03.16.22272457.

7.   Kanai, M. *et al.* Insights from complex trait fine-mapping across diverse populations.

bioRxiv (2021) doi:10.1101/2021.09.03.21262975.

8.   LaPierre, N. *et al.* Identifying causal variants by fine mapping across multiple studies. *PLoS*

Genet. **17**, e1009733 (2021).

9.   Kichaev, G. & Pasaniuc, B. Leveraging Functional-Annotation Data in Trans-ethnic Fine-

Mapping Studies. *Am. J. Hum. Genet.* **97**, 260–271 (2015).

10. Wyss, A. B. *et al.* Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry

loci for pulmonary function. *Nat. Commun.* **9**, 2976 (2018).

11. Gharahkhani, P. *et al.* Genome-wide meta-analysis identifies 127 open-angle glaucoma loci

with consistent effect across ancestries. *Nat. Commun.* **12**, 1258 (2021).

12. Robertson, C. C. *et al.* Fine-mapping, trans-ancestral and genomic analyses identify causal

variants, cells, genes and drug targets for type 1 diabetes. *Nat. Genet.* **53**, 962–971 (2021).

13. Wang, G., Sarkar, A., Carbonetto, P. & Stephens, M. A simple new approach to variable

selection in regression, with application to genetic fine mapping. *J. R. Stat. Soc. Series B*

Stat. Methodol. **82**, 1273–1300 (2020).

14. Sudlow, C. *et al.* UK biobank: an open access resource for identifying the causes of a wide

range of complex diseases of middle and old age. *PLoS Med.* **12**, e1001779 (2015).

15. Feng, Y.-C. A. *et al.* Taiwan Biobank: A rich biomedical research database of the

Taiwanese population. *Cell Genomics* **2**, 100197 (2022).

16. Mitchell, T. J. & Beauchamp, J. J. Bayesian Variable Selection in Linear Regression. *J. Am.*

Stat. Assoc. **83**, 1023–1032 (1988).

17. George & McCulloch. Approaches for Bayesian variable selection. *Stat. Sin.*

18. Kichaev, G. *et al.* Integrating functional data to prioritize causal variants in statistical fine-

mapping studies. *PLoS Genet.* **10**, e1004722 (2014).

19. International HapMap Consortium. A haplotype map of the human genome. *Nature* **437**,

1299–1320 (2005).

20. Lonjou, C. *et al.* Linkage disequilibrium in human populations. *Proc. Natl. Acad. Sci. U. S.*

A. **100**, 6069–6074 (2003).

21. Shi, H. *et al.* Population-specific causal disease effect sizes in functionally important

regions impacted by selection. *Nat. Commun.* **12**, 1098 (2021).

22. Ning, Z., Pawitan, Y. & Shen, X. High-definition likelihood inference of genetic correlations

across human complex traits. *Nat. Genet.* **52**, 859–864 (2020).

23. Abell, N. S. *et al.* Multiple causal variants underlie genetic associations in humans. *Science*

375, 1247–1254 (2022).

24. Liu, C.-C., Liu, C.-C., Kanekiyo, T., Xu, H. & Bu, G. Apolipoprotein E and Alzheimer

disease: risk, mechanisms and therapy. *Nat. Rev. Neurol.* **9**, 106–118 (2013).

25. Tehranchi, A. *et al.* Fine-mapping cis-regulatory variants in diverse human populations.

Elife **8**, (2019).

26. Marigorta, U. M. & Navarro, A. High trans-ethnic replicability of GWAS results implies

common causal variants. *PLoS Genet.* **9**, e1003566 (2013).

27. Li, Y. R. & Keating, B. J. Trans-ethnic genome-wide association studies: advantages and

challenges of mapping in diverse populations. *Genome Medicine* vol. 6 Preprint at

https://doi.org/10.1186/s13073-014-0091-5 (2014).

28. Lam, M. *et al.* Comparative genetic architectures of schizophrenia in East Asian and

European populations. *Nat. Genet.* **51**, 1670–1678 (2019).

29. Ulirsch, J. C. *et al.* Interrogation of human hematopoiesis at single-cell and single-variant

resolution. *Nature Genetics* vol. 51 683–693 Preprint at https://doi.org/10.1038/s41588-019-

0362-6 (2019).

30. Weissbrod, O. *et al.* Functionally informed fine-mapping and polygenic localization of

complex trait heritability. *Nat. Genet.* **52**, 1355–1363 (2020).

31. Ulirsch, J. C. & Kanai, M. An annotated atlas of causal variants underlying complex traits

and gene expression. *Under review*.

32. Chen, C.-Y. *et al.* Analysis across Taiwan Biobank, Biobank Japan and UK Biobank

identifies hundreds of novel loci for 36 quantitative traits. *medRxiv* (2021).

33. Wang, Q. S. *et al.* Leveraging supervised learning for functionally informed fine-mapping of

cis-eQTLs identifies an additional 20,913 putative causal eQTLs. *Nat. Commun.* **12**, 3394

(2021).

34. Li, H. Toward better understanding of artifacts in variant calling from high-coverage

samples. *Bioinformatics* **30**, 2843–2851 (2014).

35. Karczewski, K. J. *et al.* Author Correction: The mutational constraint spectrum quantified

from variation in 141,456 humans. *Nature* **590**, E53 (2021).

36. McLaren, W. *et al.* The Ensembl Variant Effect Predictor. *Genome Biol.* **17**, 122 (2016).

37. Pruim, R. J. *et al.* LocusZoom: regional visualization of genome-wide association scan

results. *Bioinformatics* **26**, 2336–2337 (2010).

38. Benner, C. *et al.* FINEMAP: efficient variable selection using summary data from genome-

wide association studies. *Bioinformatics* **32**, 1493–1501 (2016).

39. Benner, C. *et al.* Prospects of Fine-Mapping Trait-Associated Genomic Regions by Using

Summary Statistics from Genome-wide Association Studies. *Am. J. Hum. Genet.* **101**, 539–

551 (2017).

40. Cui, R. *et al.* Improving fine-mapping by modeling infinitesimal effects. *bioRxiv*

2022.10.21.513123 (2022) doi:10.1101/2022.10.21.513123.

41. Zhou, W. *et al.* Global Biobank Meta-analysis Initiative: Powering genetic discovery across

human disease. *Cell Genomics* **2**, 100192 (2022).

42. Su, Z., Marchini, J. & Donnelly, P. HAPGEN2: simulation of multiple disease SNPs.

Bioinformatics **27**, 2304–2305 (2011).

43. 1000 Genomes Project Consortium *et al.* A global reference for human genetic variation.

Nature **526**, 68–74 (2015).

44. Chang, C. C. *et al.* Second-generation PLINK: rising to the challenge of larger and richer

datasets. *Gigascience* **4**, 7 (2015).

45. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of

genomewide association scans. *Bioinformatics* **26**, 2190–2191 (2010).

Extended Data Figure 1: Schematic illustration of meta-based, *post hoc* and SuSiEx fine-mapping methods. All panels were created following the LocusZoom style[17]. Variant positions are shown on the x axis. The gold diamond for each locus represents the lead (most associated) variant. The association strengths for other variants are colored by descending degrees of linkage disequilibrium (LD) with the lead variant (ordered red, orange, green, and blue dots). The purple bars represent the posterior inclusion probability (PIP) inferred by fine-mapping methods. The light gray boxes represent the credible set estimated by fine-mapping. **a1-a5**, Example of a strong causal signal shared across populations. **b1-b5**, Example of a weak causal signal shared across populations. **c1-c5**, Example of a population-specific causal signal.

Extended Data Figure 2: Comparison of SuSiEx, PAINTOR and MsCAVIAR in simulations.
a, The job completion summary for the three Bayesian fine-mapping methods using different parameters and input datasets. Red stands for jobs taking longer than 24 hours. Yellow stands for jobs returning unreasonable results, defined as the sum of PIP across variants in the genomic locus >5 or <0.1 (1 is expected). Green stands for jobs that were completed within 24 hours and returned reasonable results. **b**, Number of identified true causal SNPs with PIP >0.5 (x-axis) versus the coverage of credible sets (y-axis) for different input datasets and fine-mapping methods. Color represents the combination of discovery populations; size of the symbols represents the total discovery sample size, and the shape of the symbols represents different methods and parameters. Only simulation runs that were completed within 24 hours and returned reasonable results were included.

Extended Data Figure 3: Examples of the improvement of SuSiEx over single-population fine-mapping in biobank analysis. Each of the three sub-figures consists of eight panels, which are aligned vertically, with the x-axis representing the genomic position. The top six panels visualize GWAS association statistics and single-population fine-mapping results of the European (Pan-UKBB Europan), African (Pan-UKBB African) and East Asian (Taiwan biobank) populations. For association statistics, the left y-axis represents the -$\log_{10}$(p-value) of each SNP. The color stands for the descending degrees of LD with the lead SNP (from red, orange to blue). The right y-axis represents the recombination rate in the centimorgan per Megabase. The solid line indicates the population-specific recombination maps obtained from the 1000 Genomes Project. Different colors were used to distinguish different credible sets in the fine-mapping results. The second to bottom panel visualizes results from SuSiEx. The bottom panel shows gene annotations if any. **a**, Association with albumin on chr8:9,170,000-9,190,000, an example of a strong causal signal shared across populations. **b**, Association with platelets count on chr12:104,900,000-105,050,000, an example of a weak causal signal shared across populations. **c**, Association with albumin on chr12:13,100,000-13,400,000, an example of population-specific causal signals.

Extended Data Figure 4: Association with total bilirubin on chr11: 5,100,000-5,700,000.
Panels are aligned vertically, with the x-axis representing the genomic position. The top six panels visualize GWAS association statistics and single-population fine-mapping results of the European (Pan-UKBB Europan), African (Pan-UKBB African) and East Asian (Taiwan biobank) populations following the LocusZoom[37] style. The second to bottom panel visualizes the fine-mapping results from SuSiEx, which integrated GWAS summary statistics from the three populations. The bottom panel shows gene annotations. For GWAS panels, the left y-axis represents the $-\log_{10}$(p-value) of each SNP. The gray horizontal dash line represents the genome-wide significance threshold (5×10^{-8}). The purple rectangle for each locus represents the lead (most associated) variant. Variants are colored by descending LD with the lead variant (ordered red, orange, green, light blue, and dark blue dots). For fine-mapping panels, different colors were used to distinguish different credible sets. The diamond represents the maximum PIP variant of each credible set. The left y-axis represents the PIP from fine-mapping and the right y-axis represents the recombination map obtained from the 1000 Genomes Project (for the SuSiEx panel, the average recombination rate across three populations was used).

Extended Data Figure 5: Association with albumin on chr13: 31,150,000-31,450,000.
Panels are aligned vertically, with the x-axis representing the genomic position. The top six panels visualize GWAS association statistics and single-population fine-mapping results of the European (Pan-UKBB Europan), African (Pan-UKBB African) and East Asian (Taiwan biobank) populations following the LocusZoom[37] style. The second to bottom panel visualizes the fine-mapping results from SuSiEx, which integrated GWAS summary statistics from the three populations. The bottom panel shows gene annotations. For GWAS panels, the left y-axis represents the -log₁₀(p-value) of each SNP. The gray horizontal dash line represents the genome-wide significance threshold (5×10^{-8}). The purple rectangle for each locus represents the lead (most associated) variant. Variants are colored by descending LD with the lead variant (ordered red, orange, green, light blue, and dark blue dots). For fine-mapping panels, different colors were used to distinguish different credible sets. The diamond represents the maximum PIP variant of each credible set. The left y-axis represents the PIP from fine-mapping and the right y-axis represents the recombination map obtained from the 1000 Genomes Project (for the SuSiEx panel, the average recombination rate across three populations was used).

Extended Data Figure 6: Proportion of variants showing quality issues binned by the drop in PIP from single- to multi-population fine-mapping. Quality issues were defined as (i) the best PIP variant is in the low complexity region; (ii) the best PIP variant is in allelic imbalance or violates Hardy Weinberg equilibrium in gnomAD[33]; or (iii) the best PIP variant is multi-allelic or colocalizes with indels at the same genomic position, which might influence imputation quality.

Extended Data Figure 7: Proportion of variants with high/moderate functional impact in cross-population biobank fine-mapping analyses. The functional impact of each variant was annotated using VEP, with the definition and classification of functional impact obtained from https://useast.ensembl.org/info/genome/variation/prediction/predicted_data.html. The high impact category includes transcript ablation, splice acceptor variants, splice donor variants, etc; moderate impact includes missense variants, protein-altering variants, etc; low impact includes synonymous variants, splice region variants, etc; modifier impact includes introns and intergenic variants among others.